0 64

Cited 0 times in

Clinical investigation of botulinum toxin (prabotulinumtoxin A) for bruxism related to masseter muscle hypertrophy: A prospective study

Authors
 Bok Ki Jung  ;  Hojin Park  ;  Young Woo Cheon  ;  In Sik Yun  ;  Jong-Woo Choi  ;  Han Jo Kim  ;  Mu Young Lee  ;  Byeong Su Kang  ;  Tae Jo Kang 
Citation
 JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, Vol.51(5) : 332-337, 2023-05 
Journal Title
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY
ISSN
 1010-5182 
Issue Date
2023-05
MeSH
Botulinum Toxins, Type A* / therapeutic use ; Bruxism* / complications ; Bruxism* / drug therapy ; Humans ; Hypertrophy / drug therapy ; Injections, Intramuscular ; Masseter Muscle / diagnostic imaging ; Neuromuscular Agents* / therapeutic use ; Prospective Studies
Keywords
Botulinum toxins ; Bruxism ; Masseter muscle
Abstract
This study aims to confirm the effectiveness and safety of a prabotulinumtoxin type A (praBTX-A) injection in patients with bruxism and masseter hypertrophy. The study included patients who ground or clenched their teeth while sleeping and had computed tomography (CT) scans that showed a maximum thickness of the masseter muscle of 15 mm or more. The praBTX-A was administered bilaterally into the masseter muscles; 15 U/side for group 1, 25 U/side for group 2, and 35 U/side for group 3. CT scans and bruxism questionnaires were conducted before and eight weeks after the injection. Thirty-seven patients were enrolled, but three dropped out due to loss of follow-up. After injection, masseter thickness decreased to 15.1 ± 2.0 mm for group 1, 14.3 ± 2.9 mm for group 2, and 13.4 ± 1.8 mm for group 3 (p = 0.043). Group 3 showed a statistically significant lower masseter thickness compared to group 1 (p = 0.039). Both subjective and objective frequencies of bruxism decreased for all groups, but there were no significant differences in either subjective (p = 0.396) or objective frequencies (p = 0.87) between the groups after the injection. The results of this study suggest that praBTX-A injection is a safe and effective treatment for bruxism and masseter hypertrophy. A dosage of 35 IU/side can effectively decrease masseter thickness and relieve bruxism symptoms. Even the minimum dosage of 15 IU/side can contribute to improvements in bruxism symptoms. This investigation provides valuable information for managing bruxism that is associated with hypertrophic masseter muscles.
Full Text
https://www.sciencedirect.com/science/article/pii/S1010518223000768
DOI
10.1016/j.jcms.2023.05.005
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Plastic and Reconstructive Surgery (성형외과학교실) > 1. Journal Papers
Yonsei Authors
Yun, In Sik(윤인식) ORCID logo https://orcid.org/0000-0003-1103-7047
Jung, Bok Ki(정복기) ORCID logo https://orcid.org/0000-0002-4347-560X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/196752
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links